Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy

Inclusion Criteria:

* 1\. Male and female subjects ≥18 years of age；
* 2.Patients prepared to receive hepatectomy；
* 3.50×10\^9/L≤platelet count≤80×10\^9/L；
* 4.Child-PUgh score A or grade B (≤7 )；
* 5.Life expectancy ≥3 months；
* 6.Normal Bone marrow hematopoiesis and renal function;
* 7.Voluntary participation and written informed consent;

Exclusion Criteria:

* 1.Central nervous system diseases caused by liver disease;
* 2.Platelet transfusion within 7 days prior to the first dose of study drug;
* 3.History of any primary hematologic disorder;
* 4.History of arterial or venous thrombosis, including thrombosis of any part of the splenic-mesenteric system;
* 5.Pre-diagnosed Immune Thrombocytopenic Purpura (ITP);
* 6.History of Myelodysplastic Syndrome (MDS);
* 7.Those with bleeding tendency，have evidence of hereditary bleeding or blood coagulation disorder;
* 8.Females who are pregnant (positive β-hCG test ) or breastfeeding;
* 9.Subjects who have participated in another investigational trial within 30 days prior to Visit 1;
* 10.Those with uncontrollable neurological and psychiatric diseases or mental disorders, poor compliance, unable to cooperate and describe treatment response;
* 11.Subjects with known intolerance or allergy to any of the ingredients in eltrombopag tablets;